Skip to main content
. Author manuscript; available in PMC: 2017 Feb 16.
Published in final edited form as: Acta Neuropathol. 2016 Oct 11;133(1):43–60. doi: 10.1007/s00401-016-1627-0

Table 1.

Patient information, Patients are grouped by diagnosis and whether they were further investigated by genetic analysis. Final columns list results of plasma ELISAs (Fig.6). Patients who were included in previous studies are denoted by a, b, or c. PB: plasmablast, CBA: cell based assay for aquaporin-4 reactivity, AZT: azathioprine

Patient Sex Age Diagnosis
at Draw		 Current
Diagnosis		 Relapses MRI
Changes		 Treatment at
Draw		 Current
Treatment		 Percent
of PBs
in Blood		 Percent
of PBs
in CSF		 PBs
Sorted
from
Blood		 Number of
Productive
PB
Sequences		 Plasma
Brain
ELISA		 Plasma
Sy5y
ELISA
CIS Patients Included inGenetic Analysis CIS924a M 69 TM TM 0 0 None None 7.1 33.3 144 47 + +
CIS799a F 28 CIS RRMS 0 0 None Avonex 5.74 13.3 190 68 + +
CIS991a F 34 CIS TM 0 0 None steroids 3.3 15.4 73d 25 + +
CIS111abc F 62 CIS PPMS 0 0 None Avonex 3.04 5.77 190d 58 - +
CIS663a F 32 TM TM 0 0 None None 2.85 10.8 192 121 - +
CIS431abc F 27 CIS RRMS 1 1 None Gilenya 2.07 35.9 190d 81 + +
ATM4 M 24 CIS RRMS 0 0 Prednisone None 1.54 16.1 176 28 + -
CIS353abc F 58 CIS RRMS 1 1 None Copaxone 1.46 11.4 190d 51 + +
CIS683abc F 39 CIS RRMS 0 0 None Tecfidera 0.82 26.6 190d 63 - -
CIS Patients Not Included inGenetic Analysis CIS287ac F 45 TM TM 0 0 None Betaseron 6.58 37.9 - -
CIS873ac F 19 RRMS RRMS 0 0 None Avonex 2.98 26 + +
CIS527ac F 43 CIS RRMS 0 0 None Copaxone 1.81 14.1 - -
CIS699a F 37 CIS RRMS 0 0 None Avonex 1.61 7.87 - +
CIS787ac M 33 CIS RRMS 0 0 None Copaxone 1.45 36.9 - +
CIS251ac F 53 TM Sarcoidosis 0 0 None None 1.43 2.57
CIS942a F 52 CIS CIS 0 0 None Copaxone 1.19 12.2 - -
CIS328ac M 32 CIS RRMS 0 0 None Avonex 0.64 2.41 - -
CIS371ac F 56 CIS CIS 0 0 None Copaxone 0.51 13.9
Patient Sex Age Diagnosis at Draw Current Diagnosis AQP-4 Status AQP-4 Test Treatment at Draw Current Treatment Percent of PBs in Blood Percent of PBs inCSF PBs SortedFrom Blood Number of Productive Sequences Plasma Brain ELISA Plasma Sy5y ELISA
NMO Patientsin GeneticAnalysis NM0.1 F 55 NMO NMO + ELISA None Cellcept 3.47 n/a 95 31 + +
NM0.2 F 36 NMO NMO + ELISA None None 0.22 n/a 83 15
NM0.7 F 54 NMO NMO + CBA None Cellcept 4.09 n/a 94 32
NM0.8 F 64 NMO NMO + CBA None Rituxan 2.43 n/a 94 25
NMO Patients Not Included inGenetic Analysis NM0.3 F 39 NMO NMO - CBA Cellcept Cellcept 1.05 n/a - -
NM0.4 F 61 NMO NMO + ELISA Cellcept Cellcept 0.09 n/a - -
NM0.5 F 41 NMO NMO + ELISA Cellcept Rituxan 1.08 n/a - -
NM0.6 M 47 NMO NMO - CBA Cellcept Rituxan 1.01 n/a - -
NM0.9 F 53 NMO NMO - CBA Cellcept Cellcept 1.34 n/a - -
NMO.10 F 61 NMO NMO + ELISA Cellcept Cellcept 0.17 n/a - -
NM0.31 F 46 NMO NMO + Unknown AZT Unknown 0 n/a
NM0.33 M 38 NMO NMO + Unknown Cellcept Unknown 5.97 n/a
NMO.70 F 45 NMO NMO + Unknown AZT Unknown 4.52 n/a
NMO.260 F 47 NMO NMO - Unknown Cellcept Unknown 3.02 n/a
NM0.626 M 36 NMO NMO - Unknown AZT Unknown 2.15 n/a
NMO.740 F 29 NMO NMO _ Unknown AZT Unknown 3.13 n/a
NM0.745 F 50 NMO NMO Unknown Unknown Cellcept Unknown 1.66 n/a
a

CSF and peripheral B cells previously studied by flow cytometry.

b

Peripheral B cells previously studied by genetic analysis.

c

CSF B cell previously studied by genetic analysis.

d

Memory B cells also sorted (productive/total sorted): CIS991: (49/95) CIS111: (14/94) CIS431: (71/188) CIS353: (54/190) CIS683: (61/188)